By Professor Andrew David Carr

Journal articles

Puls R; Carr AD, 2003, 'Practical applications of the HIV lipodystrophy case definition', AIDS Reader, 13, pp. 480 - 481

Mallon PW; Miller J; Cooper DA; Carr AD, 2003, 'Prospective evaluation of the effects of antiretroviral therapy on body composition and metabolic parameters in HIV-1-infected men starting therapy', AIDS, 17, pp. 979

Mallon PW; Wand HC; Law MG; Miller JM; Cooper DA; Carr AD, 2003, 'Strong association between buffalo hump and high serum insulin concentrations in HIV-infected individuals', Antiviral Therapy, 8, pp. L61 - L61

Vanhems P; Voirin N; Hirschel B; Cooper DA; Vizzard J; Carr AD; Perrin L, 2003, 'Swiss HIV Cohort Study. Incubation and duration of specific symptoms at acute retroviral syndrome as independent predictors of progression to AIDS', Journal of Acquir Immun Defic Syndrome, 32, pp. 542 - 544

Petoumenos K; Carr AD, 2003, 'The role of observational data in monitoring trends in antiretroviral treatment and HIV disease stage: results from the Australian HIV Observational database', Journal of Clinical Virology, 26, pp. 209 - 222

Smith DG; Carr AD; Law MG; Martin A; Hoy JF; Hudson J; Cooper DA, 2003, 'Thymidine analogue withdrawal for patients on protease sparing therapy improves lipoatrophy but compromises antivrial control:the PIILR extension study', AIDS, 16, pp. 2489 - 2491, http://journals.lww.com/aidsonline/fulltext/2002/12060/thymidine_analogue_withdrawal_for_lipoatrophic.20.aspx

Carr AD, 2003, 'Toxicity of antiretroviral therapy and implications for drug development', Nature Rev Drug Discov, 2, pp. 624 - 634

Carr A; Cooper DA, 2002, 'Fumagillin for intestinal microsporidiosis', NEW ENGLAND JOURNAL OF MEDICINE, 347, pp. 1381 - 1381, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000178781300027&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Carr A; Cooper DA; Molina JM; Tourneur M, 2002, 'Fumagillin for intestinal microsporidiosis [4] (multiple letters)', New England Journal of Medicine, 347, pp. 1381, http://dx.doi.org/10.1056/NEJM200210243471719

Mikhailof N; Carr A; Amin J; Cooper DA, 2002, 'Insulin resistance and HIV-related lipoatrophy [1] (multiple letters)', Journal of the American Medical Association, 288, pp. 1716, http://dx.doi.org/10.1001/jama.288.14.1716

French M; Amin J; Roth N; Carr A; Law M; Emery S; Drummond F; Cooper D; investigators* OBOO2, 2002, 'Randomized, open-Label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 Infection: The OzCombo 2 study', HIV Research & Clinical Practice, 3, pp. 177 - 185, http://dx.doi.org/10.1310/hct.2002.3.3.001

Carr A; Cooper D; Darbyshire J; Dubé M; Peto T; Raghavan S; Reiss P; Walker S; Weller I; Zackin R, 2002, 'The evaluation of metabolic function and fat redistribution in clinical trials', HIV Medicine, 3, pp. 65 - 72, http://dx.doi.org/10.1046/j.1464-2662.2001.00099.x

Moyle G; Carr A, 2002, 'HIV-associated lipodystropy, metabolic complications, and antiretroviral toxicities', HIV Clinical Trials, 3, pp. 89 - 98

Miller J; Brown DA; Amin J; Kent-Hughes J; Law MG; Cooper DA; Carr AD, 2002, 'A randomised, double-blind study of gemfibrozil for the treatment of protease inhibitor-associated hypertriglyceridaemia', AIDS, 16, pp. 2195 - 2200

Carr AD; Workman C; Smith DE; Hoy JF; Hudson J; Doong N; Martin A; Amin J; Freund J; Law MG; Cooper DA, 2002, 'Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy', JAMA - Journal of the American Medical Association, 288, pp. 207 - 215

Gan SK; Samaras K; Thompson CH; Kraegen EW; Carr AD; Cooper DA; Chisholm DJ, 2002, 'Altered myocellular and abdominal fat partitioning predict disturbance in insulin action in HIV protease inhibitor-related lipodystrophy', Diabetes, 51, pp. 3163 - 3169

Wilkinson J; Zaunders J; Carr AD; Guillemin GJ; Cooper DA, 2002, 'Characterization of the phenotypic and lymphokine profile associated with strong CD8+ anti-HIV-1 suppressor activity (CASA', Clinical and Experimental Immunology, 127, pp. 145 - 150

Vanhems P; Routy J; Hirschel B; Baratin D; Vora S; Carr AD; Maenza J; Trepo C; Touraine JL; Gillibert R; Collier AC; Cooper DA; Vizzard J; Sekaly R; fabry J; Perrin L, 2002, 'Clinical features of the acute retroviral syndrome differ by route of infection but not by gender and age', Journal of Acquir Immun Defic Syndrome, 31, pp. 318 - 321

Carr AD; Workman C; Smith DE; Hoy JF; Doong N; Amin J; Law MG; Cooper DA, 2002, 'For the MITOX investigators: Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial', Journal of the American Medical Association, 288, pp. 207 - 215

Carr AD; Cooper DA, 2002, 'Fumagillin for microsporidiosis', New England Journal of Medicine, 347, pp. 1381 - 1381

Carr AD; Cooper DA, 2002, 'Fumagillin treatment of intestinal microsporidiosis', New England Journal of Medicine, 347, pp. 1381

Mallon PW; Carr AD; Cooper DA, 2002, 'HIV-associated lipodystrophy: description, pathogenesis, and molecular pathways', Current Diabetes Reports, 2, pp. 116 - 124

Carr AD, 2002, 'Improvement of the study, analysis, and reporting of adverse events associated with antiretroviral therapy', The Lancet, 360, pp. 81 - 85

Carr AD; Amin J; Cooper DA, 2002, 'Insulin resistance and HIV-related lipoatrophy', Journal of the American Medical Association, 288, pp. 1716

Carr AD, 2002, 'Liver dysfunction associated with antiretroviral therapy', HIVINSITE, pp. 1

Schambelan M; Benson CA; Carr AD; Currier JS; Dube MP; Gerber JG; Grinspoon SK; Grunfeld C; Kotler DP; Mulligan K; Powderly W; Saag MS, 2002, 'Management of the metabolic complications assoicated with antiretroviral therapy for HIV-1 infection:recommedations of an International AIDS society-USA', Journal of Acquir Immun Defic Syndrome, 31, pp. 257 - 275

French MA; Amin J; Roth N; Law MG; Emery S; Drummond F, 2002, 'Randomized, open-label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 infection: The OzCombo 2 Study', HIV Clinical Trials, 3, pp. 177 - 185

Baker D; Law MG; Petoumenos K; Smith DE; Anderson JA; Roth N; Mallal SA, 2002, 'Rates of combination antiretroviral treatment change in Australia, 1997-2000', HIV Medicine, 3, pp. 28 - 36

Carr AD; Law MG; Baker D; Petoumenos K; Smith D; Anderson JA; Roth N; Mallal SS, 2002, 'Rates of combination antiretroviral treatment change in Australia', HIV Medicine, 3, pp. 28 - 36

Vanhems P; Caillat-Vallet E; Hirschel B; Routy J; Carr AD; Vizzard J; Cooper DA; Perrin L, 2002, 'The CD4 cell count 3 months after acute retroviral syndrome is associated with the presence of AIDS in the source individual', AIDS, 16, pp. 2234 - 2236

Vandems V; Caillat-Vallet E; Hirschel B; Routy J; Carr AD; Vizzard J; Cooper DA; Perrin L, 2002, 'The CD4 cell count 3 months after severe retroviral syndrome is associated with the presence of AIDS in the source individual', AIDS, 16, pp. 2234 - 2236

Smith DE; Carr AD; Law MG; Hudson J; Hoy JF; Cooper DA, 2002, 'Thymidine analogue withdrawal for lipoatrophic patients on protease-sparing therapy improves lipoatrophy but compromises antiviral control: the PIILR extension study', AIDS, 16, pp. 2489 - 2491

Carr AD, 2002, 'Virologic outcomes of complex drug regimens for human immunodeficiency virus', Journal of the American Medical Association, 288, pp. 2405 - 2406

Powderly WG; Carr A, 2001, 'AIDS 2001. Clinical treatment. Overview.', AIDS, 15 Suppl 5

Powderly WG; Carr A, 2001, 'Clinical treatment', AIDS, 15, http://dx.doi.org/10.1097/00002030-200100005-00019

Mooser V; Carr A, 2001, 'Antiretroviral therapy-associated hyperlipidaemia in HIV disease', Current Opinion in Lipidology, 12, pp. 313 - 319, http://dx.doi.org/10.1097/00041433-200106000-00011

Carr A; Morey A; Mallon P; Williams D; Thorburn DR, 2001, 'Fatal portal hypertension, liver failure, and mitochondrial dysfunction after HIV-1 nucleoside analogue-induced hepatitis and lactic acidaemia', Lancet, 357, pp. 1412 - 1414, http://dx.doi.org/10.1016/S0140-6736(00)04579-7

Blanco F; Carr A, 2001, 'Lipodystrophy syndrome: Diagnostic, clinic and therapeutic aspects', AIDS Reviews, 3, pp. 98 - 105

Carr A, 2001, 'Osteopenia in HIV infection.', AIDS clinical care, 13

Gan SK; Samaras K; Carr AD; Chisholm DJ, 2001, 'Anti-retroviral therapy, insulin resistance and lipodystrophy', Diabetes Obesity and Metabolism, pp. 67 - 71

Carr AD; Hudson J; Chuah J; Law MG; Mallal SA; Hoy JF; Doong N; French MA; Smith DE; Cooper DA, 2001, 'HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study', AIDS, 15, pp. 1811 - 1822

Mallon PW; Cooper DA; Carr AD, 2001, 'HIV¿associated lipodystrophy.', HIV Medicine, 2, pp. 166 - 173

Zaunders J; Kaufmann GR; Cunningham PH; Smith DE; Grey PA; Suzuki K; Carr AD; Goh L; Cooper DA, 2001, 'Increased turnover of CCR5+ and redistribution of CCR5- CD4 T lymphocytes during primary human immunodeficiency virus type 1 infection.', Journal of Infectious Diseases, 183, pp. 736 - 743

Carr AD; Miller J; Eisman JA; Cooper DA, 2001, 'Osteopenia in HIV-infected men: association with asymptomatic lactic acidemia and lower weight pre-antiretroviral therapy', AIDS, 15, pp. 703 - 709

Sabin CA; Olmscheid B; Moyle G; Carr A; Boyle B; Cohen C; Cooper D; Deeks S; Gulick T; Saag M, 2001, 'Selected topics from the 8th Conference on Retroviruses and Opportunistic Infections. February 4-8, 2001. Chicago, Illinois.', HIV Clin Trials, 2, pp. 366 - 386, http://dx.doi.org/10.1310/FPDY-DK6J-GLTV-HC50

Carr AD; Baker D; Petoumenos K; Law MG; Smith D; Roth N; Anderson JA; Mallal SS, 2001, 'Time trends in antiretroviral treatment use in Australia', Venereology - the Interdisciplinary International Journal of Sexual Health, 14, pp. 162 - 168

Carr A; Yarchoan R, 2000, 'AIDS 2000. Clinical treatment: overview.', AIDS, 14 Suppl 3

Carr A, 2000, 'HIV protease inhibitor-related lipodystrophy syndrome', Clinical Infectious Diseases, 30, http://dx.doi.org/10.1086/313854

Carr A; Morey A; Cooper DA; Thorburn DR, 2000, 'Chronic liver failure and persistent mitochondrial dysfunction 2 years after nucleoside reverse transcriptase inhibitor (NRTI)-induced acute hepatitis and lactic acidemia', AIDS, 14, pp. S64 - S64, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000165192300211&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Carr A, 2000, 'Lipodystrophy syndrome: Developing a case definition', AIDS, 14, pp. S13 - S13, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000165192300040&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Back to profile page